Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval to manufacture and market RAN™-Cefprozil Tablets, 250mg and 500mg, and RAN™-Cefprozil  Powder for Oral Suspension, 250mg/5mL from Health Canada.  The total market size for Cefzil™* in Canada was CAD 28.2 million dollars (IMS-MAT: Dec 2006). 

Cefprozil Tablets and Powder for Oral Suspension are indicated for the treatment of upper respiratory tract infections, uncomplicated skin and urinary tract infections.

“We are pleased to receive these approvals for RAN™-Cefprozil, Tablets and Powder for Oral Suspension to expand the number of product offerings that Ranbaxy commercializes for use by patients who require the therapeutic benefits of this product where indicated.  This further adds to our expanding generic product portfolio which will have benefits of offering an affordable generic alternative to the brand that will now be accessible to all Canadians,”  according to Bill Abboud, President, RPCI.

Ranbaxy Pharmaceuticals Canada Inc., (RPCI) based in Mississauga, Ontario, Canada, is a wholly subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company.  RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Sourced From: Ranbaxy Laboratories Ltd